We recently updated our Privacy Notice and Terms of Use.
Med-IQ
<em>Decision-IQ:</em> Assessing Risk and Preventing Tumor Lysis Syndrome
Decision-IQ Decision-IQ

Decision-IQ: Assessing Risk and Preventing Tumor Lysis Syndrome


Released:
6/15/18
Expires:
6/14/19

Maximum Credits:

0.25
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Decision-IQ Decision-IQ
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
6/15/18

Expires:
6/14/19

Maximum Credits:
0.25
Decision-IQ Decision-IQ
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
6/15/18
Expires:
6/14/19


Maximum Credits:
0.25


Overview: This brief case-based, digital CME activity incorporates current evidence-based prophylaxis algorithms to assess the risk of tumor lysis syndrome (TLS) in a patient with chronic lymphocytic leukemia (CLL) undergoing anticancer therapy. Links to relevant literature and expert insights are provided to help clinicians prevent and manage TLS.

CME Information:

Faculty
Farrukh T. Awan, MD, MS
Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, OH
 
Activity Planners
Iwona Misiuta, PhD, MHA
Clinical Content Manager
Med-IQ
Baltimore, MD
 
Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Lead Nurse Planner
Med-IQ
East Lansing, MI
 
Learning Objective
Upon completion, participants should be able to:

  • Implement evidence-based prophylaxis algorithms to mitigate the risk of TLS in patients undergoing potent anticancer therapy

Target Audience
This activity is intended for hematologist/oncologists and medical oncologists.
 
Statement of Need
The consequences of rapid cancer cell lysis observed as a result of certain treatments for several hematologic malignancies and select solid tumors—known as tumor lysis syndrome (TLS)—can result in serious complications and even death without aggressive preventive and management measures. With the continuous improvement in the armamentarium of available anticancer therapies, this metabolic emergency is increasingly observed in patients with malignancies not historically considered to be high risk, including chronic lymphocytic leukemia (CLL). However, guidelines for preventing and managing TLS in high-risk patients with CLL are based largely on expert consensus. Hematologist/oncologists and medical oncologists must therefore become skilled in the identification of patients with underappreciated TLS risk and proper techniques to prevent and manage this potentially fatal complication.
 
Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Medium/Method of Participation
This CME activity consists of a 0.25-credit publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: June 15, 2018
Expiration Date: June 14, 2019
Estimated Time to Complete This Activity: 15 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
 
Farrukh T. Awan, MD, MS
Consulting fees/advisory boards: AbbVie Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Pharmacyclics LLC
Contracted research: Pharmacyclics LLC
 
The peer reviewers and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information        
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email info@med-iq.com.
 
Hardware/Software Requirements
Operating System
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer

Browser
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Download: http://www.mozilla.org/en-US/firefox/new/
 
Google Chrome - latest version
Download: http://www.google.com/chrome
 
Apple Safari - latest version
Download: http://www.apple.com/safari/download/

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader
Download: http://get.adobe.com/reader/

Adobe Flash Player 
Adobe Flash Player 9 or later
Download: http://get.adobe.com/flashplayer/ 
 
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support.
 
ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
 
Copyright
© 2018 Med-IQ, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.